Medtronic (MDT) is back in focus after GE HealthCare introduced a digital link between its bkActiv intraoperative ultrasound system and Medtronic’s Stealth AXiS surgical navigation platform for cranial procedures.

The integration news lands while Medtronic’s share price sits at US$87.21, with a 90 day share price return of a 10.05% decline and a year to date share price return of a 9.20% decline, even as the 1 year total shareholder return stands at 8.54% and the 3 year total shareholder return at 19.11%. This suggests price momentum has cooled recently compared with the longer term experience for holders.

If this kind of operating room technology interests you, it can be worth scanning the wider medical and AI ecosystem to see what else is gaining attention, starting with 31 healthcare AI stocks

With Medtronic trading at US$87.21, alongside an indicated 4.76% intrinsic discount and a 25.63% gap to analyst targets, is the stock still on sale or is the market already pricing in future growth?

Most Popular Narrative: 8.2% Undervalued

According to the widely followed Medtronic narrative, a fair value of $95 sits ahead of the current $87.21 share price, which is why some investors see upside in the story Evangelos lays out.

Diverse Product Portfolio: Medtronic operates across four key segments, Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes, providing revenue stability and reducing dependency on any single product line. This diversification surpasses more specialized competitors like Boston Scientific (focused on cardiovascular) or Intuitive Surgical (robotics).

Curious what earnings profile and profit margins sit behind that valuation gap? The narrative leans on cash generation, segment breadth, and future profitability assumptions that are not obvious from the share price chart.

Result: Fair Value of $95 (UNDERVALUED)

However, you still need to watch for regulatory setbacks or product recalls, as well as continued pressure in the diabetes unit, either of which could weaken this undervaluation story.

Next Steps

If this mix of headwinds and potential rewards leaves you undecided, now is a good time to review the data and clarify your own stance by weighing the 6 key rewards

Looking for more investment ideas?

Once you have a view on Medtronic, do not stop there. Broaden your watchlist with other opportunities that match your style and risk comfort.

• Target steady cash payouts by reviewing companies that currently appear as 11 dividend fortresses.
• Hunt for potential value opportunities by scanning the 58 high quality undervalued stocks that might deserve a closer look.
• Prioritize resilience by checking companies highlighted in the 72 resilient stocks with low risk scores before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.